We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Race Space have created an endurance event directory for the 21st century that is designed to uncomplicate the online experience of finding and entering events.  
days to go: Expired investment: £111,583
iBan Wallet has created an app which allows users to be in control of their finances, connecting them to the people involved in any transaction. They will create a space for investors and also for borrowers, allowing the borrowers to be in control of the amount of interest they pay. 
days to go: Expired investment: £111,648
An app to help local independent businesses gain more exposure on the High Street. Sizzl will create bespoke marketing by using cinematography to tell stories for locals in the area to view on their smartphones. Investment will provide Sizzl with the infrastructure for a monthly subscription payment system and initial marketing to attract small businesses.
days to go: Expired investment: £25,490
Appital is an emerging financial market platform that will use digital profiling, unique algorithms and notifications to connect institutional demand and supply. With Appital, corporate and institutional companies within the equity capital markets space will have the opportunity to exchange illiquid equity without an investment bank or broker. Appital will also remove the dependence on email and phone, thereby ensuring efficiency and accessibility. The company is raising fund to built the Appital software, achieve FCA regulation, generate marketing material and gain contracts with partner settlement and KYC providers. Furthermore, the company will enhance the functionality of the software by leveraging its network to other products such as primary debt and primary equity deal flow.
days to go: Expired investment: £349,060
Oval Money is the leading European automated saving and crowd investing marketplace that brings simple access and diversification to investment solutions for people who don't have large sums of initial capital. The company is backed by major VC investors and supported by the largest banks in Europe.
days to go: Expired investment: £626,310
We are a property Market Place matching Buyers and Sellers, Landlords and Tenants without the use of estate agents. The online portal will dramatically reduce the fees that sellers and landlords pay agents to find buyers and tenants for their properties
days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph